We are developing first-in-class non-virally delivered genetic medicines for renal indications leveraging proprietary LNPs to deliver to the kidney and tunable to various cell types within the kidney. We are starting with ADPKD, which affects over 12 million people worldwide, where patients have only management options with very poor quality of life. We are creating a potential best-in-class gene editing-based approach, where with 1 therapy we are able to cater to 85% of the patient population, where we aim to not only halt cyst progression but potentially reverse some of it. We also are leveraging our delivery technology to develop a robust renal franchise. We operate from Bayer Co.Lab Cambridge and India. Helex is seeking BD collaborations, co-development partnerships for renal indications, and licensing opportunities for our kidney-targeted LNP platform.